Biotech Showcase™ 2017: Rexgenero readies cell therapy for Critical Limb Ischemia Phase III

January 19, 2017
Founded as recently as 2014, Rexgenero is poised to start two Phase III trials of its lead candidate Rexmyelocel-T (REX-001) in patients with Critical Limb Ischemia. CEO Dr. Joe Dupere tells Mike Ward, Informa Pharma Intelligence’s insights global director of content, that the London-based cell therapy company is seeking new investors and potential partners for Asian and Middle Eastern markets.
Previous Video
Biotech Showcase™ 2017: Shield pilots ironclad specialty future with Feraccru
Biotech Showcase™ 2017: Shield pilots ironclad specialty future with Feraccru

Bolstered with a successful launch in Germany and the UK of its anemia treatment Feraccru, Shield Therapeut...

Next Video
Biotech Showcase™ 2017: Keryx looks to label expansion to drive Auryxia
Biotech Showcase™ 2017: Keryx looks to label expansion to drive Auryxia

After a stuttering launch and relaunch, Keryx Biopharmaceuticals CEO Greg Madison revealed to Mike Ward, In...